Tidal Therapeutics Overview

  • Founded
  • 2019
Founded
  • Status
  • Private
  • Latest Deal Type
  • Early Stage VC
  • Investors
  • 2

Tidal Therapeutics General Information

Description

Developer of technology intended to modify T-cells directly in the patient's blood, targeting myeloma and B-cell malignancies. The company is developing novel CAR T therapies, providing doctors solutions for multiple myeloma treatments.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Other Healthcare Technology Systems
Primary Office
  • 49 Sycamore Road
  • Quincy, MA 02171
  • United States
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Tidal Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC 01-Jan-2020 Completed Startup
1. Seed Round 01-Jul-2019 Completed Startup
To view Tidal Therapeutics’s complete valuation and funding history, request access »

Tidal Therapeutics Executive Team (2)

Name Title Board Seat Contact Info
Matthias Stephan Scientific Co-Founder
Ulrik Nielsen Ph.D Co-Founder, Chief Executive Officer, President and Board Member
To view Tidal Therapeutics’s complete executive team members history, request access »

Tidal Therapeutics Board Members (1)

Name Representing Role Since
Johannes Fruehauf Ph.D Self Board Member 000 0000
To view Tidal Therapeutics’s complete board members history, request access »

Tidal Therapeutics Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
MRL Ventures Fund Corporate Venture Capital Minority 000 0000 000000 0
Myeloma Investment Fund Corporate Venture Capital Minority 000 0000 000000 0
To view Tidal Therapeutics’s complete investors history, request access »